Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
05 oct. 2018 10h01 HE
|
Selecta Biosciences, Inc.; Généthon
Represents a potentially powerful strategy to modulate vector immunogenicity and may open new therapeutic avenues for AAV vector-mediated gene transfer EVRY, France and WATERTOWN, Mass., Oct. 05,...
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
27 sept. 2018 07h30 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018
25 sept. 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
20 sept. 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018
10 sept. 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
31 août 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update
08 août 2018 08h00 HE
|
Selecta Biosciences, Inc.
Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide better and more sustained serum uric acid control, fewer flares and less...
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018
02 août 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call
01 août 2018 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
15 juin 2018 05h30 HE
|
Selecta Biosciences, Inc.
3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA)...